<code id='DE67DFA631'></code><style id='DE67DFA631'></style>
    • <acronym id='DE67DFA631'></acronym>
      <center id='DE67DFA631'><center id='DE67DFA631'><tfoot id='DE67DFA631'></tfoot></center><abbr id='DE67DFA631'><dir id='DE67DFA631'><tfoot id='DE67DFA631'></tfoot><noframes id='DE67DFA631'>

    • <optgroup id='DE67DFA631'><strike id='DE67DFA631'><sup id='DE67DFA631'></sup></strike><code id='DE67DFA631'></code></optgroup>
        1. <b id='DE67DFA631'><label id='DE67DFA631'><select id='DE67DFA631'><dt id='DE67DFA631'><span id='DE67DFA631'></span></dt></select></label></b><u id='DE67DFA631'></u>
          <i id='DE67DFA631'><strike id='DE67DFA631'><tt id='DE67DFA631'><pre id='DE67DFA631'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:5943
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          JPM 2024: Verve Therapeutics looks to mainstream genome editing
          JPM 2024: Verve Therapeutics looks to mainstream genome editing

          VerveTherapeuticsCEOSekarKathiresanVerveSANFRANCISCO—Thepromiseofgenomeeditinghasgivenrisetopotentia

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Why a market frenzy over new weight loss drugs defies logic

          ChristineKao/STATThere’saspecterhauntingWallStreet.Itstartedinbiotech,wherecompaniesmakingdrugsforth